Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
==================================================================================================================================================================

* Stefanie R. Mullins
* John P. Vasilakos
* Katharina Deschler
* Iwen Grigsby
* Pete Gillis
* Julius John
* Matthew J. Elder
* John Swales
* Elina Timosenko
* Zachary Cooper
* Simon J. Dovedi
* Andrew J. Leishman
* Nadia Luheshi
* James Elvecrog
* Ashenafi Tilahun
* Richard Goodwin
* Ronald Herbst
* Mark A. Tomai
* Robert W. Wilkinson